Synageva Biopharma’s $211.5M public offering raises the bar for 2014 follow-ons
By Marie Powers
Thursday, March 6, 2014
Synageva Biopharma Corp. priced the largest underwritten public offering for a biotech so far in 2014, seeking to raise $211.5 million and leaving no doubt that the public markets continue to lavish capital on the rare disease space.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.